CSIMarket
 

Virax Biolabs Group Limited  (NASDAQ: VRAX)

Virax Biolabs Group Limited's

Competitiveness




 

VRAX Sales vs. its Competitors Q4 2024







Revenue Growth Comparisons




Net Income Comparison




<<  VRAX Stock Performance Comparisons


Virax Biolabs Group Limited's Comment on Competition and Industry Peers


The Company operates in competitive markets including immune profiling, research-use immune reagents, and in vitro diagnostics (IVD). Its competitors include established diagnostic companies, biotechnology firms, research reagent suppliers, contract research organizations, and emerging technology companies, many of which have greater financial, technical, regulatory, manufacturing, sales, and marketing resources. The Company is developing ViraxImmune™, a T cell immune profiling and in vitro diagnostic platform targeting post-acute infection syndromes such as Long COVID, ME/CFS, and PTLD.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Virax Biolabs Group Limited



Sources: Virax Biolabs Group Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Virax Biolabs Group Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.